Alain P Algazi

List of Publications by Year in Descending Order

57 papers	11,796 citations	31 h-index	63 g-index
63 ext. papers	14,192 ext. citations	13.6 avg, IF	5.44 L-index

#	Paper	IF	Citations
57	Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity.. *Molecular Therapy - Oncolytics*, **2022**, 25, 174-188	6.4	0
56	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. *Lancet Oncology, The*, **2021**, 22, 1692-1704	21.7	23
55	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). *Neuro-Oncology*, **2021**, 23, 1961-1973	7	24
54	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 655-664	21.7	9
53	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 643-654	21.7	58
52	Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. *Cancer Cell*, **2021**, 39, 1375-1387.e6	24.3	16
51	Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive head and neck squamous cell carcinoma: results from a multicenter, phase 2 trial.. *Clinical Cancer Research*, **2021**,	12.9	1
50	Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. *Clinical Cancer Research*, **2020**, 26, 2827-2837	12.9	43
49	Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. *Annals of Surgical Oncology*, **2020**, 27, 4122-4130	3.1	5
48	Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. *Cancer Immunology Research*, **2020**, 8, 246-254	12.5	27
47	Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. *Nature Medicine*, **2020**, 26, 1564-1568	50.5	27
46	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. *Nature Communications*, **2020**, 11, 6262	17.4	20
45	Treatment modality impact on quality of life for human papillomavirus-associated oropharynx cancer. *Laryngoscope*, **2020**, 130, E48-E56	3.6	17
44	Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers. *American Journal of Clinical Dermatology*, **2019**, 20, 781-796	7.1	5
43	A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600 mutant advanced melanoma. *Pigment Cell and Melanoma Research*, **2019**, 32, 603-606	4.5	11
42	Ultraviolet light-related DNA damage mutation signature distinguishes cutaneous from mucosal or other origin for head and neck squamous cell carcinoma of unknown primary site. *Head and Neck*, **2019**, 41, E82-E85	4.2	9
41	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. *Lancet, The*, **2019**, 393, 156-167	40	674

40	Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2018**, 41, 1083-1088	2.7	88
39	High response rate to PD-1 blockade in desmoplastic melanomas. *Nature*, **2018**, 553, 347-350	50.4	178
38	Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. *Pigment Cell and Melanoma Research*, **2018**, 31, 110-114	4.5	28
37	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. *New England Journal of Medicine*, **2018**, 379, 722-730	59.2	659
36	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-□and IL-12. *Immunity*, **2018**, 49, 1148-1161.e7	32.3	352
35	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. *Cancer Immunology Research*, **2017**, 5, 417-424	12.5	241
34	Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. *British Journal of Cancer*, **2017**, 116, 1141-1147	8.7	80
33	Head and neck cancer in 2016: A watershed year for improvements in treatment?. *Nature Reviews Clinical Oncology*, **2017**, 14, 76-78	19.4	15
32	Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). *Immunotherapy*, **2017**, 9, 1309-1321	3.8	35
31	Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	24
30	A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. *Clinical Cancer Research*, **2017**, 23, 1910-1919	12.9	48
29	SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).. *Journal of Clinical Oncology*, **2017**, 35, 2578-2578	2.2	5
28	Relationship between liver metastases and PD-1 blockade in melanoma.. *Journal of Clinical Oncology*, **2017**, 35, 3072-3072	2.2	3
27	Sexual activity and function in male cancer patients receiving targeted an immune therapies.. *Journal of Clinical Oncology*, **2017**, 35, e21594-e21594	2.2	1
26	Immune monitoring outcomes of patients with stage III/IV melanoma treated with a combination of pembrolizumab and intratumoral plasmid interleukin 12 (pIL-12).. *Journal of Clinical Oncology*, **2017**, 35, 78-78	2.2	1
25	Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors.. *Journal of Clinical Oncology*, **2017**, 35, 9558-9558	2.2	
24	Patient attitudes toward oncofertility care in male cancer patients receiving targeted and immune therapies.. *Journal of Clinical Oncology*, **2017**, 35, e21593-e21593	2.2	
23	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. *Cancer*, **2016**, 122, 3344-3353	6.4	199

22	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. *Cancer*, **2016**, 122, 3354-3362	6.4	164
21	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. *Journal of Clinical Oncology*, **2016**, 34, 871-8	2.2	206
20	Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. *Journal of Clinical Investigation*, **2016**, 126, 3447-52	15.9	325
19	Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 450-73	7.3	165
18	NCCN Guidelines Insights: Melanoma, Version 3.2016. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 945-58	7.3	66
17	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. *JAMA - Journal of the American Medical Association*, **2016**, 315, 1600-9	27.4	666
16	Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. *Cancer Cell*, **2015**, 27, 240-56	24.3	226
15	Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. *JAMA Dermatology*, **2015**, 151, 1206-1212	5.1	305
14	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. *Nature Genetics*, **2015**, 47, 250-6	36.3	320
13	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.. *Journal of Clinical Oncology*, **2015**, 33, 3003-3003	2.2	94
12	Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. *Journal of Clinical Oncology*, **2014**, 32, 3697-704	2.2	158
11	Melanoma immunotherapy. *Cancer Biology and Therapy*, **2014**, 15, 665-74	4.6	54
10	Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *New England Journal of Medicine*, **2013**, 369, 134-44	59.2	2661
9	Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *New England Journal of Medicine*, **2012**, 367, 1694-703	59.2	2048
8	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. *Lancet Oncology, The*, **2012**, 13, 1087-95	21.7	708
7	New horizons in melanoma treatment: targeting molecular pathways. *Ochsner Journal*, **2010**, 10, 93-8	1.5	1
6	Treatment of cutaneous melanoma: current approaches and future prospects. *Cancer Management and Research*, **2010**, 2, 197-211	3.6	29
5	Biology and treatment of primary central nervous system lymphoma. *Neurotherapeutics*, **2009**, 6, 587-97	6.4	28

4	Processing of auditory stimuli during auditory and visual attention as revealed by event-related potentials. *Psychophysiology*, **1994**, 31, 469-79	4.1	129
3	Intermodal selective attention. I. Effects on event-related potentials to lateralized auditory and visual stimuli. *Electroencephalography and Clinical Neurophysiology*, **1992**, 82, 341-55		186
2	Intermodal selective attention. II. Effects of attentional load on processing of auditory and visual stimuli in central space. *Electroencephalography and Clinical Neurophysiology*, **1992**, 82, 356-68		282
1	Brain potential signs of feature processing during auditory selective attention. *NeuroReport*, **1991**, 2, 189-92	1.7	46